<DOC>
	<DOCNO>NCT00563589</DOCNO>
	<brief_summary>There significant ( 50-80 % ) risk acute graft-versus-host disease ( GVHD ) early mortality ( 30 % ) associate high risk stem cell transplantation ( SCT ) match unrelated donor HLA-mismatch sibling . Mycophenolate mofetil ( MMF ) show effective safe immunosuppressant prevention treatment rejection solid organ transplantation . Its role acute GVHD prophylaxis high risk SCT investigate clinical trial .</brief_summary>
	<brief_title>Mycophenolate Mofetil Prophylaxis Graft-versus-host Disease High Risk Allogeneic Stem Cell Transplantation</brief_title>
	<detailed_description />
	<mesh_term>Graft v Host Disease</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<criteria>patient undergo allogeneic SCT high risk acute GVHD , ie . match unrelated donor one HLAlocus mismatch sibling know allergy mycophenolate mofetil</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2010</verification_date>
	<keyword>Acute graft-versus-host disease post high risk allogeneic stem cell transplantation</keyword>
</DOC>